{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:17:40Z","timestamp":1783448260083,"version":"3.55.0"},"reference-count":24,"publisher":"Bioscientifica","issue":"2","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":333,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>This study compared the efficacy and safety of two highly purified (HP) human menopausal gonadotropin (hMG) preparations, Gynogen HP and Menopur, in women undergoing controlled ovarian stimulation (COS) for in vitro fertilization (IVF). A multicenter, randomized, active-controlled noninferiority comparative study was conducted between 2019 and 2021. Women aged 21\u201340 undergoing COS for their first or second IVF cycle, with or without intracytoplasmic sperm injection, were randomized to receive either Gynogen HP or Menopur. The primary endpoint was to determine the total number of oocytes retrieved. Key secondary endpoints included total hMG dose, days of hMG stimulation, fertilization rate, implantation rate, clinical pregnancy rate and safety. A total of 150 patients were randomized into two groups: 77 received Gynogen HP and 73 received Menopur COS. The primary endpoint, the number of oocytes retrieved (mean \u00b1 standard deviation (SD)), was similar between the Gynogen HP (6.3 \u00b1 3.39) and Menopur (6.7 \u00b1 4.52) groups. The least square (LS) mean values were 5.9 for the Gynogen HP and 6.3 for Menopur, with an LS mean difference of \u2013 0.4 (95% CI: \u22121.83, 1.07; P = 0.6067), indicating that noninferiority as the lower limit of the 95% CI was above the non-inferiority threshold of \u22122.0. Secondary efficacy endpoints and safety analysis showed no significant differences between groups. Gynogen HP is noninferior and therapeutically equivalent to Menopur in terms of the number of oocytes retrieval, with a comparable safety profile. These results support the use of Gynogen HP for COS in women undergoing IVF as a part of assisted reproduction techniques.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lay summary<\/jats:title>\n                    <jats:p>This study compared two fertility medications (Gynogen HP and Menopur) that are used to help women recruit eggs for IVF treatment. The researchers assessed if these medications are equally potent and safe. The study involved 150 women undergoing their first or second round of IVF between 2019 and 2021. Half of the women received Gynogen HP, while another half received Menopur. The main finding was that both medications worked similarly \u2013 women on Gynogen HP recruited an average of 6.3 eggs, while those on Menopur recruited an average of 6.7 eggs. This small difference was not meaningful from a medical perspective. Other important factors, such as pregnancy rates and safety concerns, were also similar between the two medications. Researchers concluded that Gynogen HP works just as well as Menopur for IVF treatment and is equally safe to use. This means doctors can confidently prescribe either medication for women undergoing IVF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/raf-24-0132","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T12:15:41Z","timestamp":1748607341000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-13","source":"Crossref","is-referenced-by-count":0,"title":["Clinical efficacy and safety of two highly purified human menopausal gonadotropins in women undergoing\n                    <i>in<\/i>\n                    <i>vitro<\/i>\n                    fertilization"],"prefix":"10.1530","volume":"6","author":[{"given":"Kamini A","family":"Rao","sequence":"first","affiliation":[{"name":"Milann Fertility, (A Unit of BACC Healthcare) 1 , , ,","place":["Bangalore, Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geeta","family":"Khanna","sequence":"additional","affiliation":[{"name":"Ajanta Hospital & IVF Centre 2 , , ,","place":["Lucknow, Uttar Pradesh, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Bavishi","sequence":"additional","affiliation":[{"name":"Bavishi Fertility Institute 3 , , ,","place":["Ahmedabad, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N Sanjeeva","family":"Reddy","sequence":"additional","affiliation":[{"name":"Department of Reproductive Medicine & Surgery, Sri Ramachandra Medical Centre 4 , , ,","place":["Chennai, Tamil Nadu, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Mangukiya","sequence":"additional","affiliation":[{"name":"Orkid Medilife Pvt Ltd 5 , , ,","place":["Surat, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Jain","sequence":"additional","affiliation":[{"name":"GP Shekhawati Hospital 6 , , ,","place":["Jaipur, Rajasthan, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kishan","family":"PV","sequence":"additional","affiliation":[{"name":"Sanzyme P Ltd 7 , , ,","place":["Hyderabad, Telangana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"2026070713210718200_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/09513590802630120","article-title":"Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta-analysis","volume":"25","author":"Al-Inany","year":"2009","journal-title":"Gynecol Endocrinol"},{"key":"2026070713210718200_bib2","article-title":"Gonadotrophin-releasing hormone antagonists for assisted reproductive technology","volume":"4","author":"Al-Inany","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070713210718200_bib3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3109\/09513590.2013.788641","article-title":"A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF","volume":"29","author":"Alviggi","year":"2013","journal-title":"Gynecol Endocrinol"},{"key":"2026070713210718200_bib4","first-page":"283","article-title":"Ovarian hyperstimulation syndrome after stimulation with highly purified hMGfor in vitro fertilization: observational study SHOview","volume":"45","author":"Barri\u00e8re","year":"2017","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"2026070713210718200_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/bs.vh.2018.01.018","article-title":"The ovarian hyperstimulation syndrome","volume":"107","author":"Blumenfeld","year":"2018","journal-title":"Vitam Horm"},{"key":"2026070713210718200_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/hropen\/hoz008","article-title":"Required amount of rFSH, HP-hMG and HP-FSH to reach a live birth: a systematic review and meta-analysis","volume":"2019","author":"Bordewijk","year":"2019","journal-title":"Hum Reprod Open"},{"key":"2026070713210718200_bib7","volume-title":"StatPearls","author":"Choe","year":"2024"},{"key":"2026070713210718200_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s40261-018-0703-8","article-title":"Highly purified human menopausal gonadotropin (Menopur(\u00ae)): a profile of its use in infertility","volume":"38","author":"Deeks","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2026070713210718200_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.fertnstert.2011.12.016","article-title":"A randomized assessor-blind trial comparing highly purified hMG and recombinant FSH in a GnRH antagonist cycle with compulsory single-blastocyst transfer","volume":"97","author":"Devroey","year":"2012","journal-title":"Fertil Steril"},{"key":"2026070713210718200_bib10","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1093\/humrep\/det303","article-title":"The optimum number of oocytes in IVF treatment: an analysis of 2455 cycles in China","volume":"28","author":"Ji","year":"2013","journal-title":"Hum Reprod"},{"key":"2026070713210718200_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2019.100572","article-title":"Gonadotropin versus follicle-stimulating hormone for ovarian response in patients undergoing in vitro fertilization: a retrospective cohort comparison","volume":"92","author":"Ji","year":"2020","journal-title":"Curr Ther Res Clin Exp"},{"key":"2026070713210718200_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1477-7827-3-62","article-title":"Subcutaneously administered Menopur, a new highly purified human menopausal gonadotropin, causes significantly fewer injection site reactions than Repronex in subjects undergoing in vitro fertilization","volume":"3","author":"Keye","year":"2005","journal-title":"Reprod Biol Endocrinol"},{"key":"2026070713210718200_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/humupd\/dmx017","article-title":"GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type","volume":"23","author":"Lambalk","year":"2017","journal-title":"Hum Reprod Update"},{"key":"2026070713210718200_bib14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40618-014-0204-4","article-title":"Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation","volume":"38","author":"Levi Setti","year":"2015","journal-title":"J Endocrinol Investig"},{"key":"2026070713210718200_bib15","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1210\/endo-129-5-2623","article-title":"Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone","volume":"129","author":"Mannaerts","year":"1991","journal-title":"Endocrinology"},{"key":"2026070713210718200_bib16","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/humrep\/del445","article-title":"Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients","volume":"22","author":"Smitz","year":"2007","journal-title":"Hum Reprod"},{"key":"2026070713210718200_bib17","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/humrep\/der106","article-title":"Association between the number of eggs and live birth in IVF treatment: an analysis of 400135 treatment cycles","volume":"26","author":"Sunkara","year":"2011","journal-title":"Hum Reprod"},{"key":"2026070713210718200_bib18","doi-asserted-by":"crossref","DOI":"10.1530\/RAF-24-0079","article-title":"The landscape of assisted reproductive technology access in India","volume":"5","author":"Tholeti","year":"2024","journal-title":"Reprod Fertil"},{"key":"2026070713210718200_bib19","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/humrep\/dew051","article-title":"Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF\/ICSI cycles","volume":"31","author":"Toftager","year":"2016","journal-title":"Hum Reprod"},{"key":"2026070713210718200_bib20","first-page":"144","article-title":"Effectiveness of HP-hMG versus r-FSH in patients undergoing IVF\/ICSI cycles with moderate male-factor infertility","volume":"43","author":"Turhan","year":"2013","journal-title":"Turk J Med Sci"},{"key":"2026070713210718200_bib21","article-title":"Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles","volume":"2011","author":"van Wely","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026070713210718200_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.fertnstert.2020.03.029","article-title":"Randomized, assessor-blinded trial comparing highly purified human menotropin and recombinant follicle-stimulating hormone in high responders undergoing intracytoplasmic sperm injection","volume":"114","author":"Witz","year":"2020","journal-title":"Fertil Steril"},{"key":"2026070713210718200_bib23","article-title":"1 in 6 people globally affected by infertility: WHO","author":"World Health Organization (WHO)","year":"2023"},{"key":"2026070713210718200_bib24","article-title":"Infertility-Key facts","author":"World Health Organization (WHO)","year":"2024"}],"container-title":["Reproduction and Fertility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/raf.bioscientifica.com\/view\/journals\/raf\/6\/2\/RAF-24-0132.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/raf.bioscientifica.com\/downloadpdf\/journals\/raf\/6\/2\/RAF-24-0132.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article-pdf\/doi\/10.1530\/RAF-24-0132\/147209\/raf-24-0132.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article-pdf\/doi\/10.1530\/RAF-24-0132\/147209\/raf-24-0132.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:50:15Z","timestamp":1783446615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/raf\/article\/6\/2\/e240132\/26264\/Clinical-efficacy-and-safety-of-two-highly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1530\/raf-24-0132","relation":{},"ISSN":["2633-8386"],"issn-type":[{"value":"2633-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,1]]},"article-number":"e240132"}}